Drug Profile

STX 1100

Alternative Names: STX-1100

Latest Information Update: 11 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Scribe Therapeutics
Class Antihyperlipidaemics; Gene therapies; RNA
Mechanism of Action Gene expression inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Hypercholesterolaemia

Most Recent Events

11 Feb 2025 Scribe Therapeutics has patent pending for the "Compositions and methods for the targeting of pcsk9" in the multiple countries worldwide prior to February 2025
11 Feb 2025 Scribe Therapeutics plans a clinical trial for Hypercholesterolemia
16 Nov 2024 Preclinical trials in Hypercholesterolaemia in USA (Parenteral) prior to January 2025 (Scribe Therapeutics Pipeline, January 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com